Neutropenia and antibiotics: when, what, how and why?
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
12
7
2023
pubmed:
11
7
2023
entrez:
11
7
2023
Statut:
ppublish
Résumé
Our aim is to review recent literature on antibiotic use in patients with neutropenia. Prophylactic antibiotics are associated with risks and have limited mortality benefit. While early antibiotic use in febrile neutropenia (FN) is critical, early de-escalation or discontinuation may be safe in many patients. With an increasing understanding of potential risks and benefits of use and improved risk assessment, paradigms of antibiotic use in neutropenic patients are changing.
Identifiants
pubmed: 37431552
doi: 10.1097/QCO.0000000000000932
pii: 00001432-202308000-00003
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
218-227Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Zimmer AJ, Freifeld AG. Optimal management of neutropenic fever in patients with cancer. J Oncol Pract 2019; 15:19–24.
Kimura S, Akahoshi Y, Nakano H, et al. Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials. J Infect 2014; 69:13–25.
Galloway-Peña JR, Jenq RR, Shelburne SA. Can consideration of the microbiome improve antimicrobial utilization and treatment outcomes in the oncology patient? Clin Cancer Res 2017; 23:3263–3268.
Staffas A, Burgos da Silva M, van den Brink MR. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. Blood 2017; 129:927–933.
Khuat LT, Dave M, Murphy WJ. The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation. Gut Microbes 2021; 13:e196626217 pages.
Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol 2018; 36:3043–3054.
NCCN Guidelines Version 3.2022 Prevention and Treatment of Cancer-Related Infections. National Comprehensive Cancer Network; 2022. https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf . Accessed October 28, 2022.
Mikulska M, Averbuch D, Tissot F, et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect 2018; 76:20–37.
Gudiol C, Tubau F, Calatayud L, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 2010; 66:657–663.
Irfan S, Idrees F, Mehraj V, et al. Emergence of Carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study. BMC Infect Dis 2008; 8:80.
Hakki M, Humphries RM, Hemarajata P, et al. Fluoroquinolone prophylaxis selects for meropenem-nonsusceptible pseudomonas aeruginosa in patients with hematologic malignancies and hematopoietic cell transplant recipients. Clin Infect Dis 2019; 68:2045–2052.
Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007; 59:5–22.
Montassier E, Al-Ghalith GA, Ward T, et al. Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection. Genome Med 2016; 8:49.
Rattanathammethee T, Tuitemwong P, Thiennimitr P, et al. Gut microbiota profiles of treatment-naïve adult acute myeloid leukemia patients with neutropenic fever during intensive chemotherapy. PLoS One 2020; 15:e0236460.
Rashidi A, Kaiser T, Graiziger C, et al. Specific gut microbiota changes heralding bloodstream infection and neutropenic fever during intensive chemotherapy. Leukemia 2020; 34:312–316.
Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012; 55:905–914.
Shono Y, van den Brink MRM. Gut microbiota injury in allogeneic haematopoietic stem cell transplantation. Nat Rev Cancer 2018; 18:283–295.
Peled JU, Gomes ALC, Devlin SM, et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. New Engl J Med 2020; 382:822–834.
Administration USFaD. Fluoroquinolone Antimicrobial Drugs Information. https://www.fda.gov/drugs/information-drug-class/fluoroquinolone-antimicrobial-drugs-information . Published 2018. Updated 6/18/2018. Accessed 2/17/2023, 2023.
Slavin MA, Lingaratnam S, Mileshkin L, et al. Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 2011; 41:102–109.
Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016; 27:v111–v118.
Maschmeyer G, Bullinger L, Garcia-Vidal C, et al. Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Leukemia 2022; 36:1215–1226.
Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013; 98:1826–1835.
Kroll AL, Corrigan PA, Patel S, Hawks KG. Evaluation of empiric antibiotic de-escalation in febrile neutropenia. J Oncol Pharm Pract 2016; 22:696–701.
Rearigh L, Stohs E, Freifeld A, Zimmer A. De-escalation of empiric broad spectrum antibiotics in hematopoietic stem cell transplant recipients with febrile neutropenia. Ann Hematol 2020; 99:1917–1924.
Snyder M, Pasikhova Y, Baluch A. Early antimicrobial de-escalation and stewardship in adult hematopoietic stem cell transplantation recipients: retrospective review. Open Forum Infect Dis 2017; 4:ofx226.
Alegria W, Marini BL, Gregg KS, et al. Early antibiotic discontinuation or de-escalation in high-risk patients with AML with febrile neutropenia and prolonged neutropenia. J Natl Compr Canc Netw 2022; 20:245–252.
Gustinetti G, Raiola AM, Varaldo R, et al. De-escalation and discontinuation of empirical antibiotic treatment in a cohort of allogeneic hematopoietic stem cell transplantation recipients during the pre-engraftment period. Biol Blood Marrow Transplant 2018; 24:1721–1726.
la Martire G, Robin C, Oubaya N, et al. De-escalation and discontinuation strategies in high-risk neutropenic patients: an interrupted time series analyses of antimicrobial consumption and impact on outcome. Eur J Clin Microbiol Infect Dis 2018; 37:1931–1940.
Van de Wyngaert Z, Berthon C, Debarri H, et al. Discontinuation of antimicrobial therapy in adult neutropenic haematology patients: a prospective cohort. Int J Antimicrob Agents 2019; 53:781–788.
Niessen FA, van Mourik MSM, Bruns AHW, et al. Early discontinuation of empirical antibiotic treatment in neutropenic patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome. Antimicrob Resist Infect Control 2020; 9:74.
Schauwvlieghe A, Dunbar A, Storme E, et al. Stopping antibiotic therapy after 72 h in patients with febrile neutropenia following intensive chemotherapy for AML/MDS (safe study): A retrospective comparative cohort study. EClinicalMedicine 2021; 35:100855.
Paret R, Le Bourgeois A, Guillerm G, et al. Safety and risk of febrile recurrence after early antibiotic discontinuation in high-risk neutropenic patients with haematological malignancies: a multicentre observational study. J Antimicrob Chemother 2022; 77:2546–2556.
Verlinden A, Jansens H, Goossens H, et al. Safety and efficacy of antibiotic de-escalation and discontinuation in high-risk hematological patients with febrile neutropenia: a single-center experience. Open Forum Infect Dis 2021; 9:
Contejean A, Abbara S, Chentouh R, et al. Antimicrobial stewardship in high-risk febrile neutropenia patients. Antimicrob Resist Infect Control 2022; 11:52.
Le Clech L, Talarmin JP, Couturier MA, et al. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study. Infect Dis (Lond) 2018; 50:539–549.
Stern A, Carrara E, Bitterman R, et al. Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer. Cochrane Database of Syst Rev 2019; 1:CD012184.
Ishikawa K, Masaki T, Kawai F, et al. Systematic review of the short-term versus long-term duration of antibiotic management for neutropenic fever in patients with cancer. Cancers 2023; 15:1611.
Santolaya ME, Alvarez AM, Acuña M, et al. Efficacy and safety of withholding antimicrobial treatment in children with cancer, fever and neutropenia, with a demonstrated viral respiratory infection: a randomized clinical trial. Clin Microbiol Infect 2017; 23:173–178.
Aguilar-Guisado M, Espigado I, Martín-Peña A, et al. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol 2017; 4:e573–e583.
Ram R, Amit O, Adler A, et al. Antibiotic stewardship in patients after cellular therapy with febrile neutropenia- a single center prospective unblinded randomized trial. Blood 2021; 138:747.
de Jonge NA, Sikkens JJ, Zweegman S, et al. Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a noninferiority, open-label, multicentre, randomised trial. Lancet Haematol 2022; 9:e563–e572.
Nessle CN, Flora C, Sandford E, et al. High-frequency temperature monitoring at home using a wearable device: a case series of early fever detection and antibiotic administration for febrile neutropenia with bacteremia. Pediatric Blood & Cancer 2022; 69:e29835.
Verma N, Haji-Abolhassani I, Ganesh S, et al. A novel wearable device for continuous temperature monitoring & fever detection. IEEE J Transl Eng Health Med 2021; 9:2700407.
Mohty M, Malard F, Vekhoff A, et al. The Odyssee study: prevention of dysbiosis complications with autologous fecal microbiota transfer (FMT) in acute myeloid leukemia (AML) patients undergoing intensive treatment: results of a prospective multicenter trial. Blood 2018; 132:1444–11444.
Malard F, Vekhoff A, Lapusan S, et al. Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients. Nat Commun 2021; 12:3084.
DeFilipp Z, Peled JU, Li S, et al. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv 2018; 2:745–753.
Andermann TM, Rezvani A, Bhatt AS. Microbiota manipulation with prebiotics and probiotics in patients undergoing stem cell transplantation. Curr Hematol Malig Rep 2016; 11:19–28.
Weber D, Oefner PJ, Dettmer K, et al. Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation. Bone Marrow Transpl 2016; 51:1087–1092.
Wójtowicz A, Bochud PY. Risk stratification and immunogenetic risk for infections following stem cell transplantation. Virulence 2016; 7:917–929.
Lind ML, Mooney SJ, Carone M, et al. Development and validation of a machine learning model to estimate bacterial sepsis among immunocompromised recipients of stem cell transplant. JAMA Netw Open 2021; 4:e214514.
Rainess R, Campbell P, Santamala J, et al. Outcomes associated with de-escalation of antibiotics to target positive cultures when treating febrile neutropenia. J Pharm Pract 2022; 8971900221132120.